Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Expands By 206.2%

enGene Holdings Inc. (NASDAQ:ENGN) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 88,500 shares, an increase of 206.2% from the January 31st total of 28,900 shares. Based on an average daily trading volume, of 153,300 shares, the short-interest ratio is currently 0.6 days. Currently, 0.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler assumed coverage on enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target for the company. HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price for the company. UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, enGene currently has an average rating of “Buy” and a consensus price target of $25.89.

enGene Stock Up 2.9 %

enGene stock traded up $0.17 during trading on Friday, reaching $6.01. The stock had a trading volume of 31,149 shares, compared to its average volume of 130,468. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The business has a 50 day moving average price of $6.75 and a 200 day moving average price of $7.16. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $265.74 million, a PE ratio of -10.36 and a beta of -0.65.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, analysts predict that enGene will post -1.56 EPS for the current year.

Institutional Investors Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC acquired a new stake in enGene during the third quarter worth approximately $37,000. Vontobel Holding Ltd. purchased a new stake in enGene in the fourth quarter valued at $69,000. Jane Street Group LLC acquired a new position in enGene in the fourth quarter valued at $93,000. Toronto Dominion Bank purchased a new position in shares of enGene during the fourth quarter worth about $97,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of enGene by 15.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after purchasing an additional 2,080 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.